PhaseBio Pharmaceuticals (NASDAQ:PHAS) is up 14% postmarket after reporting the completion of its Phase 2a trial of PB2452.
The treatment achieved immediate and sustained reversal of ticagrelor in older and elderly subjects on dual antiplatelet therapy using ticagrelor and aspirin.
It was generally well tolerated with only minor adverse events reported.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.